Telmisartan and enalapril have shown comparable antihypertensive efficacy in nondiabetic hypertensive patients and similar efficacy in reducing proteinuria in patients with moderate renal failure ...

In a secondary analysis of renal effects, rates of dialysis or doubling of serum creatinine were similar with telmisartan (2.21%) and ramipril (2.03%) and slightly but significantly more common ...

The Food and Drug Administration (FDA) has approved Widaplik ™ (telmisartan, amlodipine and indapamide), a single pill combination therapy, for the treatment of hypertension, including as ...

Boehringer Ingelheim Pharmaceuticals has received approval for a new indication for its angiotensin II receptor blocker Micardis (telmisartan): cardiovascular risk reduction in patients aged 55 ...